The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of alterations in multiple tumor suppressor genes with poor outcomes in patients with EGFR-mutant lung cancer.
 
Paul Stockhammer
No Relationships to Disclose
 
Michael J Grant
No Relationships to Disclose
 
Anna Wurtz
No Relationships to Disclose
 
Giorgia Foggetti
No Relationships to Disclose
 
Francisco Expósito
No Relationships to Disclose
 
Jianlei Gu
No Relationships to Disclose
 
Sangyun Chung
No Relationships to Disclose
 
Fangyong Li
Consulting or Advisory Role - Yiviva
 
Zenta Walther
No Relationships to Disclose
 
Scott N. Gettinger
Research Funding - ARIAD/Takeda (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); NextCure (Inst)
 
Katerina A. Politi
Consulting or Advisory Role - AstraZeneca; Halda Therapeutics; Janssen
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); D2G Oncology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent licensed by MSKCC to Molecular MD for T790M testing
Travel, Accommodations, Expenses - AstraZeneca; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Lung Cancer Research Foundation
 
Sarah B. Goldberg
Honoraria - Amgen
Consulting or Advisory Role - AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Genzyme; Janssen; Merck; Mirati Therapeutics; Regeneron; Summit Therapeutics; Takeda
Research Funding - Amgen (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Mirati Therapeutics; Pfizer (Inst); Spectrum Pharmaceuticals (Inst)